Form 4: Director Lori Woods Receives CATX Stock Options

Perspective Therapeutics Director Lori A. Woods was granted 50,000 stock options as her 2026 annual equity award.

Summary

• Lori A. Woods, a Director of Perspective Therapeutics, Inc. (CATX), received an annual equity award for 2026.
• The award consists of 50,000 stock options, granting the right to buy common stock.
• The exercise price for these options is $5.35 per share.
• The options were granted on March 2, 2026, and will expire on March 2, 2036.
• The entire option grant vests on March 2, 2027, contingent on Ms. Woods' continued service as a Director.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard director compensation and an alignment of interests, without indicating any significant operational or financial changes.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The award represents a standard annual equity compensation, indicating ongoing commitment from the director.

Future Outlook

The vesting schedule of the options on March 2, 2027, indicates an expectation of Lori A. Woods' continued service as a Director for at least another year.

Management Comments

• The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.
• Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

Industry Context

StockSavvy.ai notes that annual equity awards for directors are a common practice across the biotechnology and pharmaceutical industries, serving to align leadership incentives with long-term shareholder value. This grant to a director of Perspective Therapeutics, a company likely focused on therapeutic development, is consistent with typical compensation structures in the sector, where long-term commitment is crucial for navigating lengthy R&D cycles and regulatory approvals.

Comparison to Industry Standards

• The grant of 50,000 stock options to a director is within the typical range for annual equity awards at small to mid-cap biotechnology companies, comparable to grants seen at companies like Xencor (XNCR) or Mirati Therapeutics (MRTX) for non-executive directors, which often range from 25,000 to 100,000 options or restricted stock units annually depending on company size and stage.
• An exercise price of $5.35, likely the market price on the grant date, is standard practice to ensure the options have intrinsic value only if the stock price appreciates.
• A one-year cliff vesting schedule (vesting in full after one year) is also common for director equity awards, promoting retention and aligning interests over a reasonable period.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value creation, as the options gain value only if the stock price increases.

Next Steps

• Lori A. Woods' continued service as a Director until at least March 2, 2027, for the options to fully vest.
• Potential exercise of options by Lori A. Woods between March 2, 2026, and March 2, 2036, if the stock price is favorable.

Key Dates

Recommendation

This Form 4 filing details a routine annual equity award to a director, which is a standard compensation practice and does not provide new information that would fundamentally alter the investment thesis for Perspective Therapeutics. It signals continued alignment of director interests with shareholders but offers no specific operational or financial catalysts for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company updates.

Keywords

Perspective Therapeutics, CATX, Lori A Woods, Stock Options, Equity Award, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership